Literature DB >> 23845691

Risk-scoring system for the individualized prediction of lymphatic dissemination in patients with endometrioid endometrial cancer.

M M AlHilli1, K C Podratz, S C Dowdy, J N Bakkum-Gamez, A L Weaver, M E McGree, G L Keeney, W A Cliby, A Mariani.   

Abstract

OBJECTIVE: To develop a risk-scoring system (RSS) for the prediction of lymphatic dissemination after hysterectomy in endometrioid endometrial carcinoma (EC).
METHODS: Patients who underwent surgery from 1/1/1999-12/31/2008 were evaluated. Patients with non-endometrioid histology, stage IV with macroscopic extrauterine disease, or receiving adjuvant therapy (excluding brachytherapy) without pelvic and/or paraaortic (P/PA) lymphadenectomy (LND) were excluded. Lymph node dissemination was defined as nodal metastasis when P/PA LND was performed or P/PA lymph node recurrence after negative LND or when LND was not performed. Logistic regression analysis was used to identify predictors for lymphatic dissemination and develop a RSS and nomogram. The RSS was assessed for calibration and verified for discrimination.
RESULTS: Overall, 883 patients were assessed of which 521 (59.0%) underwent P/PA LND and 57 (10.9%) had positive lymph nodes. Of patients who did not undergo P/PA LND (N=362) or had negative nodes (N=464), 10 (1.2%) patients had P/PA lymph node recurrence. Myometrial invasion, tumor diameter (TD), FIGO grade, cervical stromal invasion and lymphovascular space invasion were significant on univariable analysis. All preceding variables were included in a multivariable logistic model. A parsimonious model and an alternative full model not including TD were considered. The full model with TD (illustrated in nomogram) had the highest predictive ability (concordance index 0.88).
CONCLUSION: Our RSS allows accurate quantification of the probability of lymphatic dissemination and can be used as an adjunct to clinical decision-making after hysterectomy in the absence of staging. TD is an important component of the RSS and should be routinely assessed.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrial Cancer; Nomogram; Risk-Scoring Model

Mesh:

Year:  2013        PMID: 23845691     DOI: 10.1016/j.ygyno.2013.06.037

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  21 in total

1.  Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma.

Authors:  Yushen Qian; Erqi L Pollom; Chika Nwachukwu; Kira Seiger; Rie von Eyben; Ann K Folkins; Elizabeth A Kidd
Journal:  Gynecol Oncol       Date:  2017-07-11       Impact factor: 5.482

2.  Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia.

Authors:  Anthony B Costales; Kathleen M Schmeler; Russell Broaddus; Pamela T Soliman; Shannon N Westin; Pedro T Ramirez; Michael Frumovitz
Journal:  Gynecol Oncol       Date:  2014-10-12       Impact factor: 5.482

3.  Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case-control study.

Authors:  Kemal Gungorduk; Aykut Ozdemir; Ibrahim Egemen Ertas; Ilker Selcuk; Ulas Solmaz; Emre Ozgu; Emre Mat; Mehmet Gokcu; Tuba Karadeniz; Serap Akbay; Muzaffer Sanci; Mehmet Mutlu Meydanli; Duygu Ayaz; Tayfun Gungor
Journal:  Int J Clin Oncol       Date:  2014-11-08       Impact factor: 3.402

4.  Trends in Sentinel Lymph Node Mapping and Adjuvant Therapy in Endometrial Carcinoma.

Authors:  Natalia R Gómez-Hidalgo; Ling Chen; June Y Hou; Ana I Tergas; Caryn M St Clair; Cande V Ananth; Dawn L Hershman; Jason D Wright
Journal:  Cancer Invest       Date:  2018-03-22       Impact factor: 2.176

Review 5.  American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review.

Authors:  Matthew M Harkenrider; Alec M Block; Kaled M Alektiar; David K Gaffney; Ellen Jones; Ann Klopp; Akila N Viswanathan; William Small
Journal:  Brachytherapy       Date:  2016-05-31       Impact factor: 2.362

Review 6.  Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence.

Authors:  Giorgio Bogani; Sean C Dowdy; William A Cliby; Fabio Ghezzi; Diego Rossetti; Andrea Mariani
Journal:  J Obstet Gynaecol Res       Date:  2014-02       Impact factor: 1.730

7.  Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.

Authors:  Ashley S Felix; D Scott McMeekin; David Mutch; Joan L Walker; William T Creasman; David E Cohn; Shamshad Ali; Richard G Moore; Levi S Downs; Olga B Ioffe; Kay J Park; Mark E Sherman; Louise A Brinton
Journal:  Gynecol Oncol       Date:  2015-09-01       Impact factor: 5.482

8.  Development and validation of predictive model for lymph node metastasis in endometrial cancer: a SEER analysis.

Authors:  Xingchen Li; Yuan Cheng; Yangyang Dong; Jingyi Zhou; Zhiqi Wang; Xiaoping Li; Jianliu Wang
Journal:  Ann Transl Med       Date:  2021-04

9.  Just how accurate are the major risk stratification systems for early-stage endometrial cancer?

Authors:  S Bendifallah; G Canlorbe; P Collinet; E Arsène; F Huguet; C Coutant; D Hudry; O Graesslin; E Raimond; C Touboul; E Daraï; M Ballester
Journal:  Br J Cancer       Date:  2015-02-12       Impact factor: 7.640

Review 10.  Sentinel Lymph Node Mapping in Endometrial Cancer: A Comprehensive Review.

Authors:  Lirong Zhai; Xiwen Zhang; Manhua Cui; Jianliu Wang
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.